Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2013 - 2019)
Xenon Pharmaceuticals' (XENE) quarterly Non-Current Deffered Revenue came in at $709000.0 in Q4 2019, up 332.32% on a QoQ basis from $164000.0 in Q2 2015.
Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2013 - 2019) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 4 years of Non-Current Deffered Revenue data on file, last reported at $709000.0 in Q4 2019.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $709000.0 in Q4 2019; TTM through Dec 2019 was $709000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $709000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2019 stood at $709000.0, up from $164000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for XENE reached as high as $709000.0 in Q4 2019 and fell as low as $164000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xenon Pharmaceuticals | 5.71 Bn | 5.71 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 709,000.00 |
| Jun 30, 2015 | 164,000.00 |
| Mar 31, 2015 | 180,000.00 |
| Dec 31, 2014 | 157,000.00 |
| Sep 30, 2014 | 2.60 Mn |
| Dec 31, 2013 | 11.89 Mn |